Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every quarter.
Link as first comment.
@longevitytech.bsky.social
@longevitytech.bsky.socialDeep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every quarter.
Link as first comment.
Accrua by Deep Longevity uses an AI model to identify 'fast agers' via blood tests and directs them to GLP-1 treatments. The US telehealth platform is scheduled to launch in October 2026.